Rophibio Inc.
Rophibio Inc. is a biopharmaceutical company specializing in the research, development, and manufacturing of biosimilars, innovative biologics, and gene and cell therapeutics. Since its establishment in 2015, the company has developed expertise in cell line engineering, process development, analytical comparability assessment, and global clinical development for biosimilar and novel biopharmaceutical pipelines. Rophibio actively pursues international regulatory approvals and advances therapies in major indications, emphasizing scientific rigor and increased access to biologic medicines.
Industries
N/A
Rophibio Inc.
6th Floor, 33 Yeongudanji-ro 55beon-gil, Yeonsu-gu, Incheon, 21984, South Korea
Patents
Anti-STAT3 specific antibody and the pharmaceutical composition comprising thereof
2024-10-15 • US-12116403-B2
View DetailsAnti-STAT3 bispecific antibody having cell-penetrating ability, and pharmaceutical composition containing same
2021-11-30 • US-11186631-B2
View Details
Anti-STAT3 specific antibody and the pharmaceutical composition comprising thereof
2024-10-15 • US-12116403-B2
View DetailsAnti-STAT3 bispecific antibody having cell-penetrating ability, and pharmaceutical composition containing same
2021-11-30 • US-11186631-B2
View DetailsProducts
Portfolio of biosimilar candidates in major therapeutic areas including osteoporosis, oncology, ophthalmology, and autoimmune disorders. The pipeline covers a range of monoclonal antibody biosimilars and biosimilar versions of established biologics.
Development of engineered fusion proteins, cell-penetrating bispecific antibodies, and gene therapies for conditions including macular degeneration, cancer, inflammation, and autoimmune diseases.
Portfolio of biosimilar candidates in major therapeutic areas including osteoporosis, oncology, ophthalmology, and autoimmune disorders. The pipeline covers a range of monoclonal antibody biosimilars and biosimilar versions of established biologics.
Development of engineered fusion proteins, cell-penetrating bispecific antibodies, and gene therapies for conditions including macular degeneration, cancer, inflammation, and autoimmune diseases.
Expertise Areas
- Biosimilar development
- Biopharmaceuticals
- Antibody therapeutics
- Gene and cell therapy
Key Technologies
- Monoclonal antibody technology
- Cell line screening
- Fusion protein engineering
- Analytical comparability assessment
Key People
CEO
Chief Advisor
CTO, Head of R&D
EVP/CFO
Executive Director, Head of BD
Non-Executive Director
CEO
Chief Advisor
CTO, Head of R&D
EVP/CFO
Executive Director, Head of BD
Non-Executive Director
News & Updates
Received award for industry-academia collaboration on malaria diagnostic biomaterials.
Phase 3 clinical trial plan approval for Eylea biosimilar in Europe, marking a milestone in global late-stage development.
Completed global regulatory submissions for Phase 3 clinical trials in Korea, Europe, and the US for a biosimilar targeting neovascular age-related macular degeneration.
US FDA approved Phase 3 IND for Eylea biosimilar, allowing global trial initiation.
Interview with CEO highlighting biosimilar market strategy and industry experience.
Announced signing of term sheet for European rights for aflibercept biosimilar.
Received award for industry-academia collaboration on malaria diagnostic biomaterials.
Phase 3 clinical trial plan approval for Eylea biosimilar in Europe, marking a milestone in global late-stage development.
Completed global regulatory submissions for Phase 3 clinical trials in Korea, Europe, and the US for a biosimilar targeting neovascular age-related macular degeneration.
US FDA approved Phase 3 IND for Eylea biosimilar, allowing global trial initiation.
Interview with CEO highlighting biosimilar market strategy and industry experience.
Announced signing of term sheet for European rights for aflibercept biosimilar.